Senators grilled Robert F. Kennedy Jr. on if and how he would reform Medicaid and Medicare during his first confirmation hearing to become the next secretary of Health and Human Services.

An early move by the president has raised questions about what direction his second-term policy on drug costs will take.

Biden-era policies rescinded by Donald Trump could signal a significant shake-up in Medicare and Medicaid drug price reforms.

CMS ultimately selected to test three models with the ... would have had Medicare pay less for drugs that receive accelerated approvals from the Food and Drug Administration (FDA). The FDA grants accelerated approvals to promising drugs to make them ...

Through the issuance of Inauguration Day executive orders, the Trump Administration signaled its apparent intent to tackle drug pricing reforms

By establishing coding and separate payment for certain digital mental health devices, this group from CMS and the FDA hopes to improve access to care.

Of the scores of day-one executive orders (EOs) issued by President Trump, the order rescinding a Biden administration executive order on

Amid a deluge of executive actions, the Trump administration has directed federal health agencies to pause external communications, such as regular scientific reports, updates to websites and health advisories,

Robert F. Kennedy Jr. said he would follow the Trump administration’s orders on prescription drug price negotiations, a process that is overseen by the Centers for Medicare and Medicaid Services. He said he would focus on fighting chronic disease,

The U.S. Department of Health and Human Services has paused public communications until Feb. 1 as Trump appointees take control of health agencies.

Dr. Dorothy Fink, the acting secretary for the Department of Health and Human Services under President Donald Trump, has instructed the heads of every federal health agency to stop public communication.

This past year featured key developments in the prescription drug policy area, including the implementation of significant prescription drug pricing reform legislation and the election of a new administration.